Journal
MEDICAL SCIENCE MONITOR
Volume 23, Issue -, Pages 3737-3745Publisher
INT SCIENTIFIC INFORMATION, INC
DOI: 10.12659/MSM.902530
Keywords
Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Sodium-Glucose Transporter 2
Categories
Funding
- Science and Technology Foundation of Zhuhai [2015A0005]
Ask authors/readers for more resources
Background: Patients with type 2 diabetes mellitus (T2DM) have a high incidence of renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) expressions. The purpose of this study was to evaluate the anticancer activity of dapagliflozin as an SGLT2 inhibitor on RCC cell lines in vitro and in vivo. Material/Methods: qRT-PCR and Western blot were used to detect SGLT2 expression on different human renal cells. Then, flow cytometry and immunofluorescence were used to investigate the effects of dapagliflozin on cell cycle, apoptosis, and SGLT2 expression of CaKi-1 cells. Finally, a xenograft model and immunohistochemical staining were used to investigate the function of dapagliflozin in nude mice. Results: We proved that SGLT2 is highly expressed in RCC cell lines. We found that dapagliflozin exerts a higher cytotoxic effect on human RCC than on normal human renal cells, regulates the cell cycle and apoptosis, and reduces the glucose uptake and SGLT2 expression of CaKi-1 cells. Moreover, dapagliflozin inhibits tumor growth and reduces SGLT2 expression in vivo. Conclusions: Our results indicate that dapagliflozin has high efficiency and low toxicity and could be a new therapeutic target for RCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available